ESTRO 2022 - Abstract Book

S512

Abstract book

ESTRO 2022

Fig2: Change of p-value (boost vs. no boost) over increasing number of sample size.

Conclusion PROMs were successfully implemented into clinical routine and yielded a surprisingly high sensitivity detecting discrete dose-dependent radiation reactions in the breast-irradiation PEDRO pilot module. The extension of this in-house developed tool is prone to provide valuable information on subtle radiation induced toxicities and will help guide knowledge-based improvements of treatment planning and monitor changes in treatment schedules such as e.g., extreme hypofractionation.

OC-0588 Impact of persistent symptoms on long-term quality of life of cervical cancer survivors in EMBRACE I

S. Spampinato 1 , K. Tanderup 1 , R. Nout 2 , S. Smet 3 , J.C. Lindegaard 1 , L.U. Fokdal 1 , R. Pötter 4 , A. Sturdza 4 , B. Segedin 5 , I. Jürgenliemk-Schulz 6 , K. Bruheim 7 , U. Mahantshetty 8 , C. Chargari 9 , B. Rai 10 , R. Cooper 11 , E. van der Steen-Banasik 12 , M. Sundset 13 , E. Wiebe 14 , E. Villafranca 15 , E. Van Limbergen 16 , S. Chopra 17 , K. Kirchheiner 4 1 Aarhus University Hospital, Department of Oncology, Aarhus, Denmark; 2 Leiden University Medical Center, Department of Radiation Oncology, Leiden, The Netherlands; 3 Algemeen Ziekenhuis Turnhout, Department of Radiation Oncology, Turnhout, Belgium; 4 Medical University of Vienna, Department of Radiation Oncology- Comprehensive Cancer Center, Vienna, Austria; 5 Institute of Oncology Ljubljana, Department of Radiotherapy, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; 6 University Medical Centre Utrecht, Department of Radiation Oncology, Utrecht, The Netherlands; 7 The Radium Hospital, Oslo University Hospital, Department of Oncology, Oslo, Norway; 8 Tata Memorial Hospital, Department of Radiation Oncology, Mumbai, India; 9 Gustave-Roussy, Department of Radiotherapy, Villejuif, France; 10 Postgraduate Institute of Medical Education and Research, Department of Radiotherapy and Oncology, Chandigarh, India; 11 St James's University Hospital, Leeds Cancer Centre, Leeds, United Kingdom; 12 Radiotherapiegroep Arnhem, Department of Radiotherapy, Arnhem, The Netherlands; 13 St. Olavs Hospital, Clinic of Oncology and Women's Clinic, Trondheim, Norway; 14 Cross Cancer Institute and University of Alberta, Department of Oncology, Edmonton, Canada; 15 Hospital of Navarra, Department of Radiation Oncology, Pamplona, Spain; 16 University Hospital Leuven, Department of Radiation Oncology, Leuven, Belgium; 17 Tata Memorial Centre, Homi Bhabha National Institute, Advanced Centre for Treatment Research and Education in Cancer, Mumbai, India Purpose or Objective To evaluate the impact of persistent patient-reported symptoms on different aspects of quality of life (QoL) in locally advanced cervical cancer (LACC) survivors. Materials and Methods Longitudinal patient-reported outcome from the prospective, multi-institutional, observational EMBRACE I study (an international study on MRI-guided brachytherapy in LACC) was evaluated. Symptoms and QoL were prospectively scored with the EORTC questionnaires C30 and CX24 at baseline and regular follow-ups. Out of 1416 patients enrolled, 740 patients with baseline and ≥ 3 late follow-ups were analysed. Late, persistent, treatment-related symptoms (LAPERS) were defined if reported by patients ( ≥ ”a little”) for at least half of the assessments and with progression beyond baseline condition. For this analysis, gastrointestinal (GI), urinary and general/unspecific symptoms were selected (Table1). QoL aspects were linearly transformed into a continuous scale (0-100 score). Linear mixed-effects models (LMM) were applied to evaluate the long-term impact of LAPERS on QoL aspects. The percentage of reduction in QoL for patients with persistent symptoms compared to patients without persistent symptoms was evaluated by calculating the difference between the areas under the curves obtained with LMM (Figure1). Results Median follow-up was 59 months. Incidences of persistent symptoms ranged from 16% (n=118) to 37% (n=269) for abdominal cramps and hot flashes, respectively (Table1). Overall, presence of any persistent symptom impacted QoL, although with varying magnitude (Table1). The percentage of reduction in QoL aspects ranged between 1% (hot flashes and physical functioning) and 25% (need to rest/weakness and role functioning). Fatigue-related symptoms and pain showed the highest impact on all QoL aspects. Role functioning and Global health/QoL were the most impaired aspects, with reductions of ≥ 15% for the majority of individual symptoms. The reduction in role functioning in 5 years was 25% and 14% for patient with persistent need to rest and diarrhea, respectively (Figure1). Among GI symptoms, persistent abdominal cramps were the most detrimental, with reductions ranging from 14% to 20% for physical and role functioning, respectively. Among all the symptoms, persistent hot flashes resulted in the least impairment for all QoL aspects.